Table 1.
Characteristics of 269 apatinib-treated gastric cancer patients from two clinical trials included in the present study
| Without adverse eventsa
No. (%) |
With adverse events No. (%) |
P valueb | |
|---|---|---|---|
| Overall | 119 (44.24) | 150 (55.76) | |
| Trial | |||
| Phase II | 45 (37.82) | 48 (32.00) | 0.319 |
| Phase III | 74 (62.18) | 102 (68.00) | |
| Age (years) | |||
| < 30 | 2 (1.68) | 1 (0.67) | 0.319 |
| 30–39 | 10 (8.40) | 8 (5.33) | |
| 40–49 | 23 (19.33) | 26 (17.33) | |
| 50–59 | 53 (44.54) | 60 (40.00) | |
| 60–69 | 29 (24.37) | 54 (36.00) | |
| ≥ 70 | 2 (1.68) | 1 (0.67) | |
| Sex | |||
| Female | 27 (22.69) | 37 (24.67) | 0.705 |
| Male | 92 (77.31) | 113 (75.33) | |
| ECOG PS | |||
| 0 | 21 (17.65) | 32 (21.33) | 0.450 |
| 1 | 98 (82.35) | 118 (78.67) | |
| Stage at diagnosis | |||
| II | 2 (1.68) | 1 (0.67) | 0.755 |
| III | 7 (5.88) | 6 (4.00) | |
| IV | 109 (91.60) | 141 (94.00) | |
| Pathological grading | |||
| Gx | 12 (10.53) | 21 (15.11) | 0.280 |
| G1 | 6 (5.26) | 4 (2.88) | |
| G2 | 46 (40.35) | 44 (31.65) | |
| G3 | 50 (43.86) | 70 (50.36) | |
| No. of metastatic sites | |||
| ≤ 2 | 79 (66.39) | 104 (69.80) | 0.551 |
| > 2 | 40 (33.61) | 45 (30.20) | |
| Prior surgery of primary tumor | |||
| Yes | 86 (72.27) | 108 (72.00) | 0.961 |
| No | 33 (27.73) | 42 (28.00) | |
| Prior radiotherapy | |||
| Yes | 19 (15.97) | 21 (14.00) | 0.653 |
| No | 100 (84.03) | 129 (86.00) | |
| Neoadjuvant chemotherapy | |||
| Yes | 32 (26.89) | 45 (30.00) | 0.575 |
| No | 81 (73.11) | 105 (70.00) | |
| Months since diagnosisc | 15.7 (10.1–29.9) | 18.3 (11.8–31.4) | 0.1876 |
| Comorbidity | |||
| Yes | 29 (24.37) | 44 (29.33) | 0.363 |
| No | 90 (75.63) | 106 (70.67) | |
| Days since last chemotherapyc | 44 (34–91) | 46 (32–91) | 0.7310 |
| Tumor size | |||
| ≥ 5 cm | 50 (42.02) | 56 (37.33) | 0.435 |
| < 5 cm | 69 (57.98) | 94 (62.67) | |
aAdverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
b P values were calculated from chi-square or Fisher’s exact test for categorical variables, t test for normally distributed continuous variables, and Wilcoxon rank sum test for continuous and skewed variables
cPresented as median (interquartile range) ECOG PS: Eastern Cooperative Oncology Group performance status